he PsyIndex rallied nearly 36% last week following a sector-wide rally that consisted of three triple-digit gains and a series of high double-digit gains.

December 7, 2020 – December 11, 2020
The PsyIndex rallied nearly 36% last week following a sector-wide rally that consisted of three triple-digit gains and a series of high double-digit gains.

Market Performance

Weekly Performance: $188.61 (35.98%)

Sponsored by

CFN Enterprises Inc. (OTCQB: CNFN)

Top Gainers

Top Decliners

Corporate News, Deals & Listings

  • Tryp Therapeutics filed a final prospectus and announced its initial public offering. Press Release
  • Cybin Corp. signed a definitive agreement to acquire Adelia Therapeutics as part of its commitment to strategic growth. Press Release
  • Psyched Wellness Ltd. (CSE: PSYC) announced a positive toxicology assessment and provided a path to market for a legal psychedelic mushroom product. Press Release
  • Psyched Wellness Ltd. (CSE: PSYC) also added Aaron Slater to its Advisory Board. Press Release
  • Psyched Wellness Ltd. (CSE: PSYC) also completed writing the final extraction protocol and other details for its first product. Press Release
  • Revive Therapeutics Ltd. (CSE: RVV) added Dr. Joel Moody, an epidemiologist, as a Medical and Clinical Advisor. Press Release
  • Numinus Wellness Inc. (TSX-V: NUMI) announced a $10 million bought deal public offering. Press Release
  • Mydecine Innovations Group (CSE: MYCO) plans to make the first commercial export of legal psilocybin mushrooms. Press Release
  • Havn Life Sciences Inc. (CSE: HAVN) will supply psychedelic compounds to clinical studies focused on veterans and PTSD. Press Release
  • Mind Cure Health Inc. (CSE: MCUR) announced a translational research program with a focus on psychedelic compounds. Press Release
  • Mind Cure Health Inc. (CSE: MCUR) also announced that it was moving into psychedelic assisted therapy in British Columbia. Press Release
  • PharmaTher Inc. (CSE: PHRM) was granted a pre-IND meeting with the FDA for ketamine targeting Parkinson’s disease. Press Release
  • Entheon Biomedical Corp. (CSE: ENBI) announced a DMT drug supply agreement with Psygen Labs. Press Release
  • Pure Extracts Technologies Corp. (CSE: PULL) signed a letter of intent with The Nutraceutical Medicine Company. Press Release
  • BetterLife Pharma Inc. (CSE: BETR) added a next-gen psychedelic therapy to its pipeline of drugs. Press Release
  • Field Trip Health Ltd. (CSE: FTRP) increased its bought-deal financing to $17.4 million. Press Release

Featured Content

3 Ways to Invest in Psychedelic IP

The psychedelics industry has experienced a renaissance over the past two years with the launch of the Johns Hopkins Center for Psychedelic Research and a billion-dollar IPO. While there are many ways to capitalize on the industry, intellectual property will play a key role in both protecting assets and becoming a potential source of revenue.

We take a look at three companies that aim to build an intellectual property portfolio in the space.

Experts Weigh in on Industry Opportunities at CanndoraConnect

Canndora, a global media and event platform, and initiative created by Marigold Marketing & PR to support advancing women in emerging industries, hosted #CanndoraConnect: Women in Psychedelics on December 2nd, 2020. The event featured eight industry professionals and sold out with over 100 registrants from around the world.

Industry Developments

  • Psychedelics Re-Engineered for Potential Use in the Clinic via Nature
  • LSD vs. Mushrooms: Same But Different via Healthline
  • This is How Psychedelics Hack the Brain, According to Scientists via Vice